Cuprina Class A (CUPR)
Develops prescription live-larva products for chronic-wound debridement.
Something off on this page? Send us feedback.
Generates most revenue from prescription live-larva wound debridement products sold to hospitals and clinics, alongside cosmeceuticals; the listed Cayman parent manages operations through a Singapore subsidiary and relies on licensed technologies and partners.
Develops prescription bio-dressings that use sterile live Lucilia cuprina larvae to debride non-healing necrotic wounds. The MEDIFLY line is manufactured on demand in a Singapore laboratory and sold to hospitals and clinics in Singapore and Hong Kong, while FDA clearance establishes a U.S. regulatory route. The existing cosmeceutical range is sold through collaboration, online, and gym channels.
Builds wound-care adjacencies through licenses, research collaborations, and joint ventures, including bullfrog-collagen dressings, iodine-based antiseptics, medical leeches, IVF media, and medical-waste recycling. Execution depends on jurisdiction-specific approvals, clinician training, a controlled live-fly colony, external manufacturers, and partners that supply IP, products, and support. The listed Cayman parent conducts operations through an indirect wholly owned Singapore subsidiary.
Company facts
Categories
No analyst consensus on record.
Not reported.
Balance sheet, Dec 31, 2025Cash & short-term investments $2.5M · Total debt $380.5K · Total assets $6.7M · Shareholders' equity $4.0M
- Revenue
- $21.1K
- Operating income
- −$2.2M
- Net income
- −$2.1M
Reported in SGD, converted at the latest exchange rate
No dividends on record.
| Institutions4 holders · as of Mar 31, 2026 | 0.41% | 11.1K ADS | |
| Otherremainder | 99.59% | 2.67M ADS |
2.68M ADS as of Aug 28, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
The share count is from the company's May 2025 annual report; nothing newer is on file here.
The share count has not been confirmed by a second filing; stakes use it as it stands.
Some positions are filed in underlying shares, not receipts; the ratio is unknown, so no percentage.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Citadel Advisors LLCInstitution | 0.17% | 37,281 ADS | 13Fas of Mar 31, 2026 |
XTX Topco LtdInstitution | 0.17% | 35,457 ADS | 13Fas of Mar 31, 2026 |
Prospect Financial Group LLCInstitution | 0.07% | 15,317 ADS | 13Fas of Mar 31, 2026 |
UBS Group AGInstitution | 0.00% | 363 ADS | 13Fas of Mar 31, 2026 |
Jimmy Peng Siew LEE1Insiderdirector, 10 percent owner | — | — | Form 4filed Apr 21, 2026 ↗ |
| See all 7 → | |||
- This position is filed in underlying shares, not receipts; the ratio is unknown, so no percentage.
13F — a manager's quarterly holdings · Form 4 — an insider's transaction report
Insider tradesForm 4
Nothing filed in the last 12 months.
- Smith & Nephew (ADR)
Broad chronic-wound alternative from debridement through NPWT.
- Solventum
Scale leader in negative-pressure therapy and advanced dressings.
- Organogenesis
Regenerative wound biologics target the same chronic ulcers.
- Integra LifeSciences
Dermal matrices contest chronic-wound reconstruction cases.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Cuprina Class A | $2.75 | −3.17% | $7.5M | — | — | 190.4 | — |
| Smith & Nephew (ADR) | $28.58 | −0.34% | $12.04B | 19.0 | — | 1.9 | +3.7% |
| Solventum | $91.90 | −0.01% | $15.91B | 11.2 | 13.6 | 1.9 | +2.2% |
| Organogenesis | $1.68 | +0.56% | $214.9M | — | — | 0.5 | −56.7% |
| Integra LifeSciences | $16.88 | +0.42% | $1.31B | — | 6.6 | 0.8 | +0.8% |
| Median | 15.1 | 10.1 | 1.3 | +1.5% |